In a report released today, Derek Archila from Stifel Nicolaus reiterated a Hold rating on Aimmune Therapeutics (AIMT). The company’s shares opened today at $22.33, close to its 52-week low of $20.94.
“We are reiterating our Hold rating on AIMT shares after the company reported positive results from its Phase 3 ARTEMIS study for AR101. We believe among investors, it was widely expected this study would be positive based on the very positive data generated from AR101’s PALISADE Phase 3 study so we don’t see this as a major stock moving catalyst. As we previously published, we think the setup for the stock in the near term is challenged due to: (1) unfavorable risk/reward ahead of a FDA advisory committee later this year given investors are placing a high POS on approval; (2) ICER cost-effective analysis due out in April 2019 may create a headwind for peanut immunotherapies; and (3) with a potential US AR101 approval now pushed out to early 2020 since it will receive a standard review, we see limited upside catalysts for the stock.”
According to TipRanks.com, Archila is currently ranked with no stars on a 0-5 star ranking scale, with an average return of -8.1% and a 31.0% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Pacira Pharmaceuticals, and Selecta Biosciences.
Currently, the analyst consensus on Aimmune Therapeutics is a Strong Buy with an average price target of $57.29.
See today’s analyst top recommended stocks >>
Based on Aimmune Therapeutics’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $57 million. In comparison, last year the company had a GAAP net loss of $41.17 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Aimmune Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the research and development of desensitization treatments for peanut and other food allergies. Its portfolio includes the characterized oral desensitization immunotherapy system. The company was founded on June 24, 2011 and is headquartered in Brisbane, CA.